Alexander Augustyn is an Oncology physician affiliated with The University of Texas MD Anderson Cancer Center. OpenAlex indexes 66 publications with 1,918 citations (h-index 14).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1515 Holcombe Blvd
Houston, TX 770304000
Telephone
713-792-6161Provider last certified this registry record 5 May 2025.
Industry payments
3 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- PFIZER INC.Program year20251 payment
- Novocure Inc.Program year20251 payment
- Siemens Medical Solutions USA, Inc.Program year20221 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
39.5%Gabapentinoids17.1%Gabapentin100%Part D≥14 patientsBenzodiazepine9%Lorazepam100%Part D≥12 patients+ 2 more classes in this area
Respiratory
27.1%Opioid Agonist27.1%Hydrocodone-Acetaminophen100%Part D≥25 patientsCardiovascular
15.2%Antiarrhythmic9%Lidocaine Hcl Viscous100%Part D<11 patientsBlood Viscosity Reducer6.2%Pentoxifylline100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 2013–2016 per NIH RePORTER. The latest:
- Defining a Molecularly Distinct Subtype of Non Small Cell Lung Cancer
Ut Southwestern Medical Center
FY2016$4,048F30CA168264 - Defining a Molecularly Distinct Subtype of Non Small Cell Lung Cancer
Ut Southwestern Medical Center
FY2015$37,020F30CA168264 - Defining a Molecularly Distinct Subtype of Non Small Cell Lung Cancer
Ut Southwestern Medical Center
FY2014$29,726F30CA168264
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- ASCL1 Restrains ERK1/2 to Promote Survival of a Subset of Neuroendocrine Lung Cancers
Molecular Cancer Therapeutics
2024
Similar KOLs
Other experts from the same institution or the same specialty.
Hagop Kantarjian, MD
The University of Texas MD Anderson Cancer Center
Gabriel Hortobagyi, MD
The University of Texas MD Anderson Cancer Center
Jaffer Ajani, MD
The University of Texas MD Anderson Cancer Center
Funda Meric-Bernstam, MD
The University of Texas MD Anderson Cancer Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”